Tag
Pharmaceuticals
65 articles
The Indian pharmaceutical sector is experiencing a mix of strategic shifts and financial updates. Cipla reported record annual revenue exceeding ₹28,000 crore, underpinned by strong performance in both the Indian market and North America, alongside a final dividend declaration. Meanwhile, Nureca's promoter group executed a significant stake transfer via a family settlement, and Bacil Pharma is moving forward with a ₹50 crore rights issue to bolster its financial position. These developments, alongside Colinz Laboratories' open offer and Strides Pharma's stake sale, highlight ongoing restructuring and capital-raising activities within the industry, suggesting a focus on optimizing portfolios and securing growth funding amidst evolving market dynamics.
Cipla 90th AGM Reports ₹28,000 Crore Revenue
Cipla reported its highest-ever annual revenue of ₹28,000+ crore with a 21% EBITDA margin and declared a final dividend of ₹13 per share for FY26.
The Company outlined a growth strategy focused on lea
Albert David Cluster Head Resigns Effective July 4
Albert David Ltd discloses resignation of Cluster Head Saikath Banerjee effective July 4, 2026 due to personal reasons.
The resignation was formally intimated to BSE and NSE under SEBI LODR Regulation
Dugar Family's ₹54/Share Open Offer for 26% of Colinz Labs
Mandatory open offer by Annjana, Likhitta, and Antariksh Dugar with PAC Padam Dugar to acquire up to 6,54,966 shares (26%) of Colinz Laboratories at ₹54 per share, aggregating ₹3.53 crore.
Offer trigg
Aarti Drugs NCLAT Appeal Admission Hearing
Aarti Drugs Limited files appeal against Pegasus Farmaco at NCLAT Chennai.
NCLAT schedules admission hearing for the appeal on August 25, 2026.
Both parties represented by legal counsel in the appella
Nureca Promoter Group Sells 21.59% Stake
Disclosure under SEBI PIT Regulation 7(2) for an off-market disposal of equity shares by a promoter group member.
Payal Goyal transferred her entire 2,059,928 shares, representing a 21.59% stake, via
Bacil Pharma Board Approves ₹50 Crore Rights Issue
Bacil Pharma intimated BSE of a board meeting on 9th July 2026 to consider a ₹50 crore rights issue.
The board will also consider increasing authorized share capital and altering the MOA to facilitate
Cipla 90th AGM Reports ₹28,000 Crore Revenue
Cipla reported its highest-ever annual revenue of ₹28,000+ crore with a 21% EBITDA margin and declared a final dividend of ₹30 per share for FY26.
Key operational highlights include 9% YoY growth in I
Strides Completes ₹1,000M Pivot Path Stake Sale
Strides Pharma completed the sale of its majority stake in subsidiary Pivot Path to Ascent Capital-led consortium for ₹1,000 million.
The company received ₹750 million upfront, with ₹250 million defer
Solara Issues Final Forfeiture Notice for Unpaid Call Money
Solara Active Pharma Sciences issues final reminder and forfeiture notice to shareholders for unpaid first and second call money on partly paid equity shares.
Shareholders must pay ₹131.25 per share f
Norris Medicines Q1 FY27 Dematerialization Compliance
Norris Medicines Ltd filed a regulatory compliance certificate with BSE confirming dematerialization activities for Q1 FY27 ending June 30, 2026.
The company's RTA Purva Sharegistry certified that 1,7
Unjha Formulations 32nd AGM on August 14
Unjha Formulations schedules its 32nd Annual General Meeting for August 14, 2026, at its registered office in Sidhpur.
The meeting notice and annual report will be shared with stakeholders in due cour
Colinz Laboratories Exempt from SEBI Governance Reporting
Colinz Laboratories Ltd files a regulatory certificate confirming exemption from SEBI corporate governance reporting requirements.
The exemption is based on paid-up equity capital of ₹2.52 crore and n
Emcure Subsidiary Acquires 100% of Mantra Pharma Shares
Emcure's subsidiary Marcan Pharmaceuticals acquired 100% of Class E Special Shares in step-down subsidiary Mantra Pharma for CAD $50 million.
The acquisition, executed on July 2, 2026, consolidates Ma
Unichem Laboratories FY26 Results Show Revenue Decline, Subsidiary Sale
Unichem Laboratories reported 18.6% standalone revenue decline to ₹1,412 crores while net profit remained stable at ₹159 crores with 97.6% export contribution.
The company sold its Ireland subsidiary
Syngene FY26 Profit Falls 36% to ₹3.17B Despite Revenue Growth
Syngene International reported a 36% decline in consolidated net profit to ₹3,167 million for FY26, despite revenue growth of 2.6% to ₹37,387 million, impacted by exceptional items of ₹766 million.
Th
Dipna Pharmachem Independent Director Resigns
Mr. Nandish Shaileshbhai Jani resigned as Non-Executive and Independent Director effective June 10, 2026 due to personal reasons.
The resignation disclosure is made pursuant to SEBI Listing Regulation
Dipna Pharmachem Independent Director Parin Bhavsar Resigns
Mr. Parin Bhavsar resigned as Non-Executive and Independent Director of Dipna Pharmachem effective 12th May 2026.
The stated reason for resignation was pre-occupancy, with no other material reasons di
Acutaas Chemicals Promotes Anurag Shukla to General Manager
Acutaas Chemicals promoted Mr. Anurag Shukla to General Manager Operations & Unit Head - Ankleshwar, effective July 2, 2026.
The promotion designates Mr. Shukla as Senior Management Personnel, oversee
Brooks Laboratories Incorporates Wholly Owned Subsidiary
Brooks Laboratories incorporated a wholly owned subsidiary named Abridge Speciality Limited on July 2, 2026.
The subsidiary has an authorized share capital of ₹1,00,000 and will operate in pharmaceuti
Asston Pharmaceuticals Board Approves ₹27.72 Crore Preferential Issue
Board approved preferential issue of 24.1 lakh equity shares at ₹115 each to non-promoters, raising ₹27.72 crore.
Extraordinary General Meeting scheduled for July 31, 2026, to seek shareholder approva
Bank of India Insolvency Petition Against JRN Pharma
Bank of India filed an insolvency petition under Section 7 of IBC against JRN Pharma and Laboratories LLP.
The NCLT Guwahati Bench directed the petitioner to file hard copies and issue notices to the
Windlas Biotech FY26 Revenue Hits ₹9,041M with 19% Growth
Windlas Biotech reported record annual revenue of ₹9,041 million with 19% YoY growth and 13 consecutive quarters of revenue growth.
The company maintained strong profitability with adjusted EBITDA of
Sai Parenterals Australian Subsidiary Renews AUD 202M Supply Deal
Sai Parenterals' Australian subsidiary Noumed Pharmaceuticals renewed exclusive OTC supply agreement with Australia's leading pharmacy networks for 7.5 years.
The agreement is valued at AUD 202 millio
Syngene Appoints Siddharth Mittal as MD & CEO
Syngene International appointed Siddharth Mittal as Managing Director and CEO effective July 1, 2026, succeeding Peter Bains.
Mittal joins from Biocon Limited where he served as Managing Director and
Bharat Life Sciences Award 2026 Applications Open
Applications open for Bharat Life Sciences Award 2026 with Rs 7 crore grant support to recognize excellence in life sciences.
Six awards across five categories for scientists, institutions, startups,
Shelter Pharma Completes $18.3k UAE Export Order
Shelter Pharma intimated completion of an export order for Animal Healthcare products worth USD 18,300 to UAE.
The order was received from First Veterinary Medicines Trading LLC on 12th March 2026 and
Amanta Healthcare Promoters File Insider Trading Disclosures
Amanta Healthcare Ltd submits SEBI Regulation 7(2) disclosures for two promoter group members' off-market share transactions.
Promoter Bhavesh Girishbhai Patel purchased 1,000 equity shares, increasin
Glenmark Receives Six US FDA Goa Plant Observations
Glenmark discloses US FDA inspection at its Goa manufacturing facility from June 22-30, 2026.
Facility received Form 483 with six procedural observations, with no data integrity issues noted.
Company
Department of Pharmaceuticals Invites Medical Device Scheme Proposals
Department of Pharmaceuticals invites applications under SMDI scheme to boost domestic medical device manufacturing and reduce import dependence.
Marginal Investment Scheme offers ₹10 crore capital su
Bharat Parenterals Promoter Acquires 1,356 Shares
Bharat Parenterals discloses promoter share acquisition under SEBI PIT Regulation 7(2).
Promoter entity Desai Shares purchased 1,356 equity shares via on-market transactions.
Post-acquisition promoter
Marksans Pharma FY26 Net Profit Rises 60% YoY
Marksans Pharma reported audited FY26 standalone net profit of ₹3,007 million, a 60% increase from the previous year.
Consolidated revenue for FY26 reached ₹29,509 million, with a net profit attributa
Medico Intercontinental Promoter Acquires 1.37 Lakh Shares
Medico Intercontinental promoter MD Samir Shah acquired 1,36,886 equity shares via open market purchases from June 3-24, 2026.
The acquisition was disclosed under SEBI Prohibition of Insider Trading R
Ishita Pharmaceuticals Acquires 223 Shares in Ishita Drugs
Ishita Pharmaceuticals, a related party, acquired 223 shares of Ishita Drugs and Industries Ltd. via open market purchase on June 22, 2026.
The acquisition increases Ishita Pharmaceuticals' total voti
Bliss GVS Pharma Reports 14% Revenue Growth, Declares Dividend
Bliss GVS Pharma reported consolidated revenue of ₹9,271 crore with 14% growth and net profit rising 53% to ₹1,347 crore for FY26.
The company prepaid all long-term borrowings, reducing debt by 96% to
Amanta Healthcare Promoter Purchases 16,200 Shares
Amanta Healthcare Ltd files SEBI PIT Regulation 7(2) disclosure for a promoter's open-market share purchase.
Promoter Jitendrakumar J Patel purchased 16,200 equity shares at ₹24.29 per share on NSE.
T
Zydus Lifesciences Insiders' Buyback Share Acceptance
Zydus Lifesciences discloses insider share transactions under SEBI regulations related to its recent buyback offer.
Promoter Zydus Family Trust accepted 63.5 lakh shares, reducing its holding from 74.
Ishita Pharmaceuticals Acquires 55 Ishita Drugs Shares
Ishita Pharmaceuticals, a related party, acquired 55 equity shares of Ishita Drugs & Industries Ltd. via open market purchase on June 19, 2026.
The acquisition increases Ishita Pharmaceuticals' voting
Novartis India Open Offer Receives Minimal Share Tender
• Axis Capital discloses tender status for Novartis India's 26% open offer by WaveRise and ChrysCapital.
• Zero equity shares tendered in dematerialized form as of June 18, 2026.
• Only 10 physical sh
Colinz Labs 26% Open Offer at ₹54/Share
Annjana, Likhitta, and Antariksh Dugar with Padam Dugar launch a mandatory open offer for 26% of Colinz Laboratories at ₹54 per share.
The offer is triggered by their agreement to acquire 34.56% from
Ajanta Pharma FY26 Revenue Hits ₹5,453 Crore with 17% Growth
Ajanta Pharma reported strong FY26 performance with revenue growing 17% to ₹5,453 crore and PAT increasing 15% to ₹1,056 crore, crossing the ₹5,000 crore revenue milestone.
The company declared a divi
Novartis India Open Offer Receives Zero Shares Tendered
Axis Capital discloses zero equity shares were tendered on June 17, 2026, in the open offer for Novartis India.
The open offer is for acquiring up to 26% of Novartis India's voting share capital from
Shelter Pharma FY26 PAT Rises 25% to ₹9.03 Crore
• Shelter Pharma Ltd reported FY26 revenue of ₹73.13 crore and net profit of ₹9.03 crore, achieving 26% and 15% 3-year CAGRs respectively.
• The company maintains an almost debt-free balance sheet wit
Corona Remedies Reports 17% FY26 Revenue Growth to ₹1,403 Cr
Corona Remedies delivered strong FY25-26 performance with 17.28% revenue growth to ₹1,403.18 Cr and 33.45% PAT growth to ₹199.42 Cr, significantly outperforming IPM growth of 8.59%.
The company succes
Novartis India Open Offer Receives Zero Shares
Axis Capital discloses zero equity shares tendered on first day of Novartis India open offer.
No shares were received in both dematerialized and physical form by the offer's escrow and registrar.
The
Emcure FY26 Revenue Growth 16.6%, Margin Expansion
Emcure Pharmaceuticals reported FY26 revenue of ₹9,204 Cr, a 16.6% YoY growth, exceeding guidance with strong international performance.
EBITDA margin expanded 80 bps to 19.4% and Adj. PAT margin impr
Viyash Scientific Earnings Call Recording Available
Viyash Scientific intimates BSE about availability of Q4 FY24 earnings call audio recording on company website.
Earnings call was held on May 16, 2024 discussing audited financial results for quarter
Parmax Pharma Acquirers Seek Majority Control via SPA
Acquirers led by Dhiren C. Shah and Sunil C. Shah to acquire control of Parmax Pharma through share purchase agreement, preferential allotment, and open offer.
SPA executed at ₹35 per share for 43,210
Goldline Pharma FY26 PAT ₹411.71 Lakh, EPS ₹5.97
Goldline Pharmaceutical approved FY26 standalone results with PAT of ₹411.71 lakh and EPS of ₹5.97, a significant increase from previous year.
Appointed M/s. Kunal Dutt & Associates as Internal Audito
Anlon Healthcare Q4 FY26 Revenue Up 43% YoY
Anlon Healthcare reported FY26 consolidated revenue growth of 42.98% to INR 172.22 crore and PAT growth of 41.77% to INR 29.09 crore.
Management provided FY27 revenue guidance of INR 380-400 crore and
Fredun Pharmaceuticals AGM Approves 67% Profit Growth, Dividend
Fredun Pharmaceuticals reported 67% YoY net profit growth to ₹3,320.69 lakhs with 40% revenue increase to ₹63,332.65 lakhs for FY26.
The company convened its 39th AGM to approve a 7% dividend and 2:1
Laurus Labs FY26 Revenue Up 23% with Strong CDMO Growth
Laurus Labs reported FY26 revenue of ₹6,813 crore, a 23% YoY increase driven by 36% growth in CDMO business and 18% growth in Affordable Medicines.
EBITDA surged 64% to ₹1,826 crore with margins expan
Apollo Ingredients FY26 Net Profit Surges 11x to ₹70.85 Lakh
Apollo Ingredients submits 46th Annual Report for FY26, reporting standalone net profit of ₹70.85 lakh, up 11x from ₹9.75 lakh in FY25.
Company to hold AGM on June 29, 2026 to approve financial statem
Concord Biotech FY26 Revenue Declines 12% Amid Challenges
Concord Biotech reported FY26 revenue decline of 12% and PAT drop of 30% due to geopolitical headwinds, supply chain disruptions, and delayed tenders.
The company faced 3-month EU supply restrictions
ZIM Laboratories FY26 Financial Results and AGM Notice
ZIM Laboratories reported standalone revenue of ₹37,048 lakhs and net profit of ₹597 lakhs for FY26, a significant decrease from the previous year.
The company will hold its 42nd Annual General Meetin
Sanofi Consumer Healthcare India Reports 33% FY25 Profit Growth
Sanofi Consumer Healthcare India reported 33% net profit growth to ₹2,401 million and 21% revenue increase to ₹8,784 million for FY25.
Company recommends ₹75 per share dividend and convenes AGM on Jun
Innova Captab Reports 31% FY26 Revenue Growth to ₹16.3 Billion
Innova Captab achieved consolidated revenue growth of 31% to ₹16.30 billion with PAT increasing 10% to ₹1.41 billion for FY26, driven by strong domestic and export performance.
The company will hold i
Natco Pharma Q4 FY26 Net Profit Declines 34% YoY
Natco Pharma reported a 34% YoY decline in Q4 consolidated net profit to INR269 crores, including a one-time tax benefit of INR115 crores.
Management provided FY27 revenue guidance of INR3,400-3,500 c
Natural Capsules Q4 FY26 Revenue Up 55% QoQ
Natural Capsules reported Q4 FY26 consolidated revenue of ₹58.45 crore, up 55% QoQ, with EBITDA recovering to ₹1.33 crore.
Full-year FY26 revenue grew 11% to ₹187.20 crore, but EBITDA was a loss of ₹1
Parmax Pharma FY26 Net Loss at ₹4.16 Crore
Board approved audited standalone FY26 results showing net loss of ₹4.16 crore and quarterly loss of ₹58.43 lakh.
Auditors issued qualified report highlighting unsanctioned ₹3.51 crore insurance claim
Samprada & Nanhamati Trust Sells 0.46% Alkem Stake
Samprada and Nanhamati Singh Family Trust disclosed sale of 0.46% stake in Alkem Laboratories on June 2, 2026.
Trust's shareholding reduced from 18.74% to 18.28% following the transaction and distribu
Colinz Laboratories Dugar Family 15.01% Stake Acquisition
Colinz Laboratories discloses acquisition of 3,78,000 equity shares (15.01% stake) by Padam Dugar and PACs on May 21, 2026.
Disclosure made under SEBI Takeover Regulations 29(1) and 29(2) to BSE Limit
Sun Pharma Receives Promoter Group Reclassification Requests for 1.8% Stake
Sun Pharma received requests on 14 May 2026 from three promoter group members seeking reclassification to public category.
The shareholders, Sudhir Valia, Raksha Valia, and Krishna Valia, collectively
Aptus Pharma Promoter Tejash Hathi Acquires 10,000 Shares
Promoter Tejash Maheshchandra Hathi discloses acquisition of 10,000 equity shares in Aptus Pharma Limited via off-market transaction on May 11, 2026.
The acquisition increases his total holding to 785
Ghanshyam Pansuriya Acquires 14,000 Aptus Pharma Shares
Promoter Ghanshyam Pansuriya disclosed acquisition of 14,000 equity shares in Aptus Pharma Limited via off-market inter-se transfer.
His total holding increased from 5.10% to 5.31% of the company's vo
Kapilbhai Chandarana Acquires 10,000 Aptus Pharma Shares
Kapilbhai Hasmukhbhai Chandarana, a promoter group member, acquired 10,000 equity shares of Aptus Pharma Limited on May 11, 2026.
The acquisition increased his total holding from 775,000 shares (11.30